James Sabry takes over global partnering for Roche

roche
During his tenure at gRED, Sabry oversaw a series of deals, the latest of which being a partnership with Cambridge, U.K.-based Microbiotica potentially worth $534 million. (Roche)

James Sabry, who currently oversees partnering for Genentech’s R&D group, is extending his domain as Roche taps him for a new role—global head of partnering.

The position was created as the Swiss pharma’s Head of Roche Partnering, Sophie Kornowski-Bonnet, leaves for greener pastures. Instead of hiring a replacement, Roche is combining partnering operations for Roche’s pharma R&D group (pRED) and Genentech Research and Early Development (gRED).

It is a reversal from Roche’s strategy so far. The company has taken pains to keep the R&D units separate since its 2008 acquisition of Genentech, keeping the latter’s South San Francisco site open as an independent R&D center to preserve its “unique research culture.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Sabry will move to Basel and is set to start his new position on Aug. 1.

During his tenure at gRED, Sabry oversaw a series of deals, the latest of which being a partnership with Cambridge, U.K.-based Microbiotica potentially worth $534 million. The duo will use Microbiotica’s gut bacteria metagenomics platform to test samples from Genentech’s clinical trials in inflammatory bowel disease. And just before that, Genentech inked an open-ended discovery deal with Lodo Therapeutics around deriving unique, natural products from the microbial DNA found in soil. That collab could be worth nearly $1 billion.

“James brings a wealth of medical, scientific and business development expertise to successfully identify the best external innovation opportunities and bring them into the Roche Group.” Said Roche CEO Severin Schwan.

RELATED: Roche promotes Pao to replace departing pRED head Reed

“I would like to thank Sophie Kornowski-Bonnet for her many significant contributions over the 12 years of her career at Roche and wish her continued success for the future,” Schwan said.

Kornowski-Bonnet’s destination was left a mystery—she “has accepted a new opportunity,” the company said. Her departure comes two months after Roche’s former pRED chief, John Reed, signed on to lead R&D at Sanofi.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.